Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NJ › Hamilton › NPI 1629069638
Hospital

Robert Wood Johnson University Hospital at Hamilton

Robert Wood Johnson University Hospital at Hamilton was paid $28.17M by Medicaid between Jan 2018 and Dec 2024, across 264 billing codes. Its largest line is 99283, emergency room visit (moderate) — 15% of everything it billed.

33Billing provider infoROBERT WOOD JOHNSON UNIVERSITY HOSPITAL AT HAMILTON
HAMILTON, NJ 08690
33aNPI1629069638assigned 10/31/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$28.17M
24GClaims740,821
24DCodes billed264
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in New Jersey

Rank by total paid#51 of 93
Median peer was paid$30.60M
This provider vs. median0.9×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K$600K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018105,155$4.31M
2019107,005$4.02M
202075,574$2.61M
202196,832$3.78M
2022116,762$3.84M
2023132,984$5.05M
2024incomplete106,509$4.56M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 15% 21,111 20,246 $4.10M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 14% 15,796 14,905 $3.92M
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 12% 12,174 11,246 $3.33M
G0378 Hospital observation service, per hour 8.6% 3,911 3,277 $2.41M
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) 5.0% 43,664 11,239 $1.42M
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 4.4% 63,476 15,251 $1.25M
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple 3.4% 857 830 $971K
99282 Emergency department visit for the evaluation and management, low to moderate severity 2.3% 5,000 4,826 $642K
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance 2.1% 2,749 1,418 $605K
74177 Computed tomography, abdomen and pelvis; with contrast material 1.7% 3,404 3,278 $486K
11042 Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm 1.3% 1,995 1,008 $377K
OP370 1.3% 5,973 5,483 $359K
252 more codes
OP250 1.3% 42,138 $353K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 1.1% 13,784 $301K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 5,160 $260K
80053 Comprehensive metabolic panel <1% 31,907 $245K
96375 Therapeutic injection; each additional sequential IV push <1% 7,242 $242K
97150 Therapeutic procedure(s), group (2 or more individuals) <1% 7,745 $236K
70450 Computed tomography, head or brain; without contrast material <1% 4,936 $236K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 1,933 $231K
97530 Therapeutic activities, direct patient contact, each 15 minutes <1% 6,406 $217K
G0283 Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care <1% 5,961 $211K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 785 $210K
92507 Treatment of speech, language, voice, communication, and/or auditory processing disorder <1% 3,788 $205K
OP710 <1% 3,750 $203K
45380 Colonoscopy, flexible; with biopsy, single or multiple <1% 217 $201K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 36,983 $197K
77067 Screening mammography, bilateral, including computer-aided detection <1% 3,460 $197K
97162 <1% 4,074 $178K
OP272 <1% 5,319 $169K
97112 Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination <1% 7,379 $154K
96361 Intravenous infusion, hydration; each additional hour <1% 6,758 $139K
76830 Ultrasound, transvaginal <1% 1,857 $138K
96367 <1% 1,738 $137K
71046 Radiologic examination, chest; 2 views <1% 6,435 $117K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 1,437 $114K
93970 <1% 511 $113K
50590 <1% 101 $112K
45378 Colonoscopy, flexible; diagnostic, including collection of specimen(s) <1% 112 $112K
72125 Computed tomography, cervical spine; without contrast material <1% 1,157 $109K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 9,174 $107K
93971 <1% 793 $99K
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r <1% 2,873 $97K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 3,411 $90K
76642 <1% 1,144 $76K
36415 Collection of venous blood by venipuncture <1% 33,926 $69K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 2,602 $67K
78815 Positron emission tomography (PET) for limited area imaging <1% 64 $67K
77063 Screening digital breast tomosynthesis, bilateral <1% 2,641 $66K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 3,578 $64K
93975 <1% 393 $63K
97161 <1% 1,712 $61K
71045 Radiologic examination, chest; single view <1% 6,414 $59K
72110 <1% 1,488 $57K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 1,804 $56K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 5,238 $52K
C1776 Joint device (implantable) <1% 18 $52K
71275 Computed tomographic angiography, chest, with contrast material <1% 346 $51K
OP279 <1% 2,148 $51K
71250 <1% 474 $50K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 1,177 $49K
G0463 Hospital outpatient clinic visit for assessment and management of a patient <1% 4,258 $48K
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 319 $44K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 2,367 $43K
84443 Thyroid stimulating hormone (TSH) <1% 3,795 $41K
97116 <1% 3,267 $39K
73564 <1% 1,183 $38K
77080 <1% 674 $37K
73630 <1% 1,584 $36K
84484 <1% 8,982 $34K
73130 <1% 1,514 $33K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 2,098 $33K
G0279 Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) <1% 1,108 $32K
72148 Magnetic resonance imaging, lumbar spine; without contrast material <1% 121 $30K
73030 <1% 1,152 $27K
85610 <1% 9,934 $27K
80048 Basic metabolic panel (calcium, ionized) <1% 4,523 $25K
74018 <1% 1,608 $23K
97163 <1% 519 $23K
OP259 <1% 5,745 $23K
80061 Lipid panel <1% 2,672 $22K
82948 <1% 3,557 $22K
C1713 Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) <1% 99 $22K
77065 Tomosynthesis, mammo <1% 435 $21K
85730 <1% 8,236 $21K
83880 <1% 2,499 $20K
73610 <1% 1,078 $19K
77066 Tomosynthesis, mammo <1% 269 $19K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 6,851 $19K
87086 Culture, bacterial; quantitative colony count, urine <1% 6,104 $19K
83735 <1% 7,561 $18K
76700 Ultrasound, abdominal, real time with image documentation; complete <1% 229 $18K
82550 <1% 6,300 $17K
84439 <1% 1,276 $16K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 3,751 $16K
73560 <1% 523 $16K
J3010 Injection, fentanyl citrate, 0.1 mg <1% 3,759 $15K
83036 Hemoglobin; glycosylated (A1C) <1% 2,624 $15K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 735 $15K
86901 <1% 2,329 $15K
87040 <1% 2,586 $14K
84702 <1% 2,259 $14K
81001 <1% 9,231 $14K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 1,164 $14K
A9270 Non-covered item or service <1% 9,486 $14K
73721 Magnetic resonance imaging, any joint of lower extremity; without contrast material <1% 36 $14K
OP258 <1% 17,632 $14K
82248 <1% 1,171 $14K
97164 <1% 353 $13K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 1,281 $13K
86900 <1% 2,292 $12K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 3,627 $12K
J2704 Injection, propofol, 10 mg <1% 4,789 $11K
83690 <1% 6,357 $11K
84703 <1% 4,742 $11K
72100 <1% 582 $10K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 407 $10K
86850 <1% 1,597 $9K
87081 <1% 4,494 $9K
81003 <1% 5,263 $8K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 688 $8K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 4,110 $8K
0240U <1% 366 $8K
93017 <1% 60 $8K
96376 <1% 1,434 $8K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 471 $8K
OP270 <1% 882 $8K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 2,790 $7K
82728 <1% 756 $7K
J0690 Injection, cefazolin sodium, 500 mg <1% 2,130 $7K
99213 Doctor's office visit, returning patient (routine) <1% 369 $7K
97014 <1% 877 $6K
82962 <1% 4,536 $6K
83605 <1% 1,476 $6K
84100 <1% 3,457 $6K
72050 <1% 108 $6K
92567 <1% 77 $6K
88342 <1% 477 $6K
87186 <1% 1,634 $6K
87428 <1% 436 $6K
73110 <1% 273 $6K
0001A <1% 182 $5K
84481 <1% 230 $5K
0002A <1% 174 $5K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 382 $5K
82607 <1% 432 $5K
83540 <1% 1,161 $5K
87077 <1% 1,231 $5K
85379 <1% 1,932 $4K
94060 <1% 25 $4K
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 184 $4K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 1,493 $4K
73502 <1% 268 $4K
85652 <1% 1,170 $4K
82553 <1% 662 $4K
72170 <1% 166 $4K
70553 Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences <1% 12 $4K
83550 <1% 533 $3K
C9290 Injection, bupivacaine liposome, 1 mg <1% 113 $3K
88313 <1% 860 $3K
86141 <1% 833 $3K
76536 <1% 52 $3K
97166 <1% 78 $3K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 393 $3K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 5,811 $3K
82150 <1% 1,519 $3K
92557 <1% 12 $2K
84466 <1% 624 $2K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 326 $2K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 27 $2K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 276 $2K
87070 <1% 355 $2K
73562 <1% 117 $2K
76775 <1% 41 $2K
87205 <1% 592 $2K
85027 <1% 867 $2K
C1769 Guide wire <1% 283 $2K
70486 <1% 41 $2K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 81 $2K
90715 <1% 214 $2K
36591 <1% 145 $2K
87807 <1% 609 $2K
70551 Magnetic resonance imaging, brain; without contrast material <1% 28 $2K
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries <1% 65 $2K
45385 Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) <1% 13 $2K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 15 $2K
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 1,353 $2K
76815 Ultrasound, pregnant uterus, real time with image documentation, limited <1% 40 $1K
0004A <1% 40 $1K
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 860 $1K
88304 <1% 56 $1K
97535 Self-care/home management training, each 15 minutes <1% 198 $1K
86140 <1% 506 $1K
87088 <1% 532 $1K
J2270 Injection, morphine sulfate, up to 10 mg <1% 1,892 $1K
88312 <1% 742 $1K
J1756 Injection, iron sucrose, 1 mg <1% 60 $1K
81025 <1% 1,305 $1K
94729 <1% 25 $1K
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 680 $988.35
0012A <1% 25 $889.94
0011A <1% 25 $849.94
A9575 Injection, gadoterate meglumine, 0.1 ml <1% 497 $788.97
85007 <1% 539 $771.19
96368 <1% 43 $765.43
G8978 Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals <1% 506 $754.82
G8979 Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting <1% 530 $754.82
OP637 <1% 747 $734.40
94727 <1% 25 $730.43
97165 <1% 27 $708.98
12001 <1% 29 $675.04
0064A <1% 18 $630.78
87147 <1% 734 $590.24
J1170 Injection, hydromorphone, up to 4 mg <1% 1,292 $552.45
G8988 Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting <1% 94 $539.55
G8987 Self care functional limitation, current status, at therapy episode outset and at reporting intervals <1% 89 $538.55
C9803 Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <1% 30 $535.53
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 276 $497.21
J0131 Injection, acetaminophen, not otherwise specified,10 mg <1% 681 $451.38
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 196 $447.62
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 43 $435.98
74022 <1% 41 $430.23
82746 <1% 95 $393.52
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal <1% 13 $364.94
C1894 Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser <1% 116 $350.72
74019 <1% 30 $324.94
82784 <1% 46 $270.03
72040 <1% 15 $252.39
J7613 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg <1% 254 $221.74
J1644 Injection, heparin sodium, per 1000 units <1% 602 $208.01
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision <1% 13 $198.56
84145 <1% 66 $188.32
80143 <1% 47 $170.51
80320 <1% 71 $155.93
80179 <1% 42 $132.53
86334 <1% 15 $131.29
88311 <1% 39 $122.81
J1650 Injection, enoxaparin sodium, 10 mg <1% 410 $122.71
87075 <1% 13 $119.80
J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg <1% 394 $112.39
75571 <1% 91 $107.99
29125 <1% 26 $106.91
J3490 Unclassified drugs <1% 39 $98.46
82247 <1% 184 $74.66
J2003 Injection, lidocaine hydrochloride, 1 mg <1% 135 $66.69
81015 <1% 114 $63.61
84075 <1% 118 $62.95
84165 <1% 16 $58.77
83615 <1% 25 $58.29
84450 <1% 118 $50.98
84460 <1% 119 $50.04
J2919 Injection, methylprednisolone sodium succinate, 5 mg <1% 60 $47.69
J2060 Injection, lorazepam, 2 mg <1% 217 $38.49
82040 <1% 122 $31.12
84155 <1% 118 $31.12
J3370 Injection, vancomycin hcl, 500 mg <1% 26 $25.65
J1596 Injection, glycopyrrolate, 0.1 mg <1% 170 $13.57
91300 <1% 69 $5.00
J7510 Prednisolone oral, per 5 mg <1% 12 $3.00
J0687 Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg <1% 81 $2.61
J1815 Injection, insulin, per 5 units <1% 76 $2.00
G8984 Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals 0% 96 $0.00
G8985 Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting 0% 97 $0.00
0202U Oncology (prostate), multianalyte, gene expression profiling 0% 13 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBREZA, LISA (CEO)
Parent organizationRWJ BARNABAS HEALTH INC